[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523045":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":64,"collaborators":66,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":95,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Bien-Willner Physicians Group PA","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control\u002FStandard",null,"Standard patient group: advanced cancer patients receiving limited and acceptable care without access to advanced genetic testing tools or expertise; patients at facility prior to deployment of TSO500, ELIA, and molecular tumor boards.",[13],"Diagnostic Test: limited genetic testing or no testing",{"label":15,"type":10,"description":16,"interventionNames":17},"Test group","Same patient population at the same facility after deployment of TSO500, ELIA, and molecular tumor board support.",[18],"Combination Product: Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"COMBINATION_PRODUCT","Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation","TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)",[15],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DIAGNOSTIC_TEST","limited genetic testing or no testing","Minimal genetic testing for eligible patients or treatment without testing",[9],[31],{"name":32,"affiliation":33,"role":34},"Gabriel A Bien-Willner, MD, PhD","Bien-Willner Physicians Grp PA","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Haydee Diaz, MBASCP","CONTACT","3468310189","haydee@bwpgprecisionmed.com",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Lenee Bien-Willner, MS","7138578748","lbwillner@bwpgprecisionmed.com",[46],{"facility":47,"status":10,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Carolina Blood and Cancer Care Associates","Rock Hill","South Carolina","29732","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-81.02508,34.92487,{"lat":57,"lon":56},[60],{"name":61,"role":38,"phone":62,"phoneExt":10,"email":63},"Niyati Nathwani, MD","803-329-7772","nanathwani@cbcca.net",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67,70],{"name":68,"class":69},"No One Left Alone","UNKNOWN",{"name":47,"class":69},"100523045","molecular-services-and-emr-lab-integration-application-elia-for-reducing-healthcare-disparities-in-cancer-patients-100523045",false,"NCT06090513","Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients","Molecular Services and EMR-Laboratory Integration Application (ELIA) for Reducing Leakage and Improving Healthcare Disparities in Cancer Patients","Inclusion Criteria:\n\n* newly diagnosed or change in status Advanced Cancer patient (recurrent, refractory, metastatic, or high grade)\n* Cancer patient for whom genomic testing (comprehensive genomic profile (CGP)) is recommended by relevant guidelines\n\nExclusion Criteria:\n\n* Patient does not seek additional treatment\n* Patient younger than 18 years\n* Treatment provided at a tertiary medical center\n* CGP testing already performed and there is no change in patient cancer status","ALL","18 Years",{"count":81,"type":82},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to measure and try to reduce leakage in precision medicine care in the community cancer clinic. The goal of precision medicine is to identify the best possible therapy the the patient based on the biology of the tumor. Leakage is defined as a failure or inefficiency of the system that leads to dropped or lost testing, reporting or action (including drug selection). It has been observed that there are healthcare disparities in the community setting compared to academic medical centers, particularly in the use of precision medicine. The main questions the study aims to answer are:\n\n* How much leakage occurs in the use of precision medicine in the community setting?\n* Can we reduce leakage by providing access to better tools and services typically found in the academic medical centers? Participants will not be directly impacted and will receive standard of care. Measurements will be made of how often physicians select the appropriate test for patients, and how often they select the most appropriate therapy for their patients before and after the implementation of tools created to reduce leakage.\n\nWe hope to reduce leakage in with the use of advanced tools and services, and use this study as a model to improve healthcare in the community cancer setting.",[86,87,88],"Advanced Cancer","Solid Tumor, Adult","Myeloid Malignancy",[90,91,92,93,94],"Comprehensive genomic profile","molecular genetic pathology","community cancer center","healthcare disparities","precision medicine","NOT_YET_RECRUITING","2024-08-05",{"date":98,"type":99},"2024-08-06","ACTUAL",{"date":101,"type":82},"2024-10-18",{"date":103,"type":82},"2026-10-18",{"name":5,"class":6},1]